The final trials of a Russian coronavirus vaccine developed by the Gamalei National Research Center for Epidemiology and Microbiology may be completed earlier than in other countries, an expert said.   Kirill Dmitriev, the head of the Russian Direct Investment Fund, told the Vesti news programme on Rossiya-1television on Thursday that this phase 3 trial is necessary to put the vaccine into active use.   “We believe that Russia will possibly go through this phase quicker than other countries," Dmitriev said, reports TASS.